Acurx Pharmaceuticals Inc (ACXP)
2.16
+0.06
(+2.86%)
USD |
NASDAQ |
May 03, 10:58
Acurx Pharmaceuticals Enterprise Value: 25.62M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 25.62M |
| May 01, 2024 | 26.56M |
| April 30, 2024 | 27.19M |
| April 29, 2024 | 27.03M |
| April 26, 2024 | 25.14M |
| April 25, 2024 | 24.36M |
| April 24, 2024 | 24.51M |
| April 23, 2024 | 24.67M |
| April 22, 2024 | 23.72M |
| April 19, 2024 | 24.20M |
| April 18, 2024 | 26.09M |
| April 17, 2024 | 20.89M |
| April 16, 2024 | 18.68M |
| April 15, 2024 | 18.29M |
| April 12, 2024 | 20.42M |
| April 11, 2024 | 21.99M |
| April 10, 2024 | 21.83M |
| April 09, 2024 | 22.94M |
| April 08, 2024 | 22.62M |
| April 05, 2024 | 22.94M |
| April 04, 2024 | 23.41M |
| April 03, 2024 | 24.04M |
| April 02, 2024 | 26.72M |
| April 01, 2024 | 28.45M |
| March 28, 2024 | 31.13M |
| Date | Value |
|---|---|
| March 27, 2024 | 29.24M |
| March 26, 2024 | 25.30M |
| March 25, 2024 | 25.46M |
| March 22, 2024 | 23.09M |
| March 21, 2024 | 24.99M |
| March 20, 2024 | 25.77M |
| March 19, 2024 | 25.77M |
| March 18, 2024 | 33.34M |
| March 15, 2024 | 35.39M |
| March 14, 2024 | 31.73M |
| March 13, 2024 | 33.04M |
| March 12, 2024 | 33.90M |
| March 11, 2024 | 33.62M |
| March 08, 2024 | 34.63M |
| March 07, 2024 | 35.50M |
| March 06, 2024 | 35.93M |
| March 05, 2024 | 35.79M |
| March 04, 2024 | 34.92M |
| March 01, 2024 | 35.35M |
| February 29, 2024 | 34.05M |
| February 28, 2024 | 34.77M |
| February 27, 2024 | 37.81M |
| February 26, 2024 | 39.55M |
| February 23, 2024 | 38.10M |
| February 22, 2024 | 37.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
9.191M
Minimum
Sep 27 2023
72.72M
Maximum
Jun 25 2021
31.01M
Average
29.97M
Median
Enterprise Value Benchmarks
| Tonix Pharmaceuticals Holding Corp | 1.18M |
| Seelos Therapeutics Inc | 15.73M |
| PetVivo Holdings Inc | 13.98M |
| NovaBay Pharmaceuticals Inc | 2.666M |
| Palatin Technologies Inc | 23.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.115M |
| Total Expenses (Quarterly) | 5.115M |
| EPS Diluted (Quarterly) | -0.38 |
| Earnings Yield | -53.24% |